Ascitic ovarian cancer is an adequate preclinical model of carcinomatosis to study intraperitoneal chemoperfusion treatment

To study the mechanisms underlying the effects of intraperitoneal chemoperfusion and to develop the optimal chemoperfusion regimen, an animal model of peritoneal carcinomatosis closely resembles a human model of peritoneal carcinomatosis is required. In our study, the model of peritoneal carcinomato...

Full description

Bibliographic Details
Main Authors: G. S. Kireeva, O. A. Belyaeva, K. Yu. Senchik, V. G. Bespalov, A. N. Stukov, E. A. Gubareva, M. A. Maydin
Format: Article
Language:Russian
Published: Tomsk National Research Medical Center of the Russian Academy of Sciences 2019-02-01
Series:Sibirskij Onkologičeskij Žurnal
Subjects:
Online Access:https://www.siboncoj.ru/jour/article/view/963
id doaj-b5151ea339404cceb45c2768bdbbd0fa
record_format Article
spelling doaj-b5151ea339404cceb45c2768bdbbd0fa2021-07-28T21:02:05ZrusTomsk National Research Medical Center of the Russian Academy of SciencesSibirskij Onkologičeskij Žurnal1814-48612312-31682019-02-01181717810.21294/1814-4861-2019-18-1-71-78614Ascitic ovarian cancer is an adequate preclinical model of carcinomatosis to study intraperitoneal chemoperfusion treatmentG. S. Kireeva0O. A. Belyaeva1K. Yu. Senchik2V. G. Bespalov3A. N. Stukov4E. A. Gubareva5M. A. Maydin6N.N. Petrov National Medical Research Center of Oncology of the Russian Ministry of HealthN.N. Petrov National Medical Research Center of Oncology of the Russian Ministry of HealthN.N. Petrov National Medical Research Center of Oncology of the Russian Ministry of HealthN.N. Petrov National Medical Research Center of Oncology of the Russian Ministry of HealthN.N. Petrov National Medical Research Center of Oncology of the Russian Ministry of HealthN.N. Petrov National Medical Research Center of Oncology of the Russian Ministry of HealthN.N. Petrov National Medical Research Center of Oncology of the Russian Ministry of HealthTo study the mechanisms underlying the effects of intraperitoneal chemoperfusion and to develop the optimal chemoperfusion regimen, an animal model of peritoneal carcinomatosis closely resembles a human model of peritoneal carcinomatosis is required. In our study, the model of peritoneal carcinomatosis in rats with ascitic ovarian cancer was used. material and methods. There were three groups of rats with ascitic ovarian cancer: 1 – the control group (n=15) having no treatment; 2 – rats receiving normothermic intraperitoneal chemoperfusion with cisplatin, 40 mg/kg (n=12); 3 – rats receiving hyperthermic intraperitoneal chemoperfusion with cisplatin, 20 mg/kg (n=14). All animals were euthanized with subsequent autopsy. results. Ascitic ovarian cancer developed in 100 % of the animals injected with the tumor cells. The median overall survival of rats in the control group was 9.5 days. At autopsy, all rats had ascites, and rats surviving 15‒17 days after the tumor cell injection had white tumor nodes measuring 1–3 mm in the greater omentum, intestinal mesentery, parietal and visceral peritoneum. The nodes were histologically verified as metastases of low-differentiated ovarian tumor. In 2 and 5 rats from groups 2 and 3 respectively, metastases in paratracheal lymph nodes and tumor hydrothorax were detected with no evidence of peritoneal carcinomatosis. The median survival of rats in groups 2 and 3 was significantly higher than that in the control group, being 37.5 and 25.5 months, respectively (р=0,256). conclusion. This in vivo study proved that localization of ascitic ovarian tumor, development of the tumor in all animals injected with tumor cells, fast ascites progression and peritoneal carcinomatosis make this ascitic ovarian cancer an adequate preclinical model of peritoneal carcinomatosis to study intraperitoneal chemoperfusion. Further studies are needed to understand the reasons and mechanisms of the tumor hydrothorax development in rats after intraperitoneal chemoperfusion.https://www.siboncoj.ru/jour/article/view/963ascitic ovarian cancerperitoneal carcinomatosisintraperitoneal chemoperfusionpreclinical modelcisplatinratssurvival
collection DOAJ
language Russian
format Article
sources DOAJ
author G. S. Kireeva
O. A. Belyaeva
K. Yu. Senchik
V. G. Bespalov
A. N. Stukov
E. A. Gubareva
M. A. Maydin
spellingShingle G. S. Kireeva
O. A. Belyaeva
K. Yu. Senchik
V. G. Bespalov
A. N. Stukov
E. A. Gubareva
M. A. Maydin
Ascitic ovarian cancer is an adequate preclinical model of carcinomatosis to study intraperitoneal chemoperfusion treatment
Sibirskij Onkologičeskij Žurnal
ascitic ovarian cancer
peritoneal carcinomatosis
intraperitoneal chemoperfusion
preclinical model
cisplatin
rats
survival
author_facet G. S. Kireeva
O. A. Belyaeva
K. Yu. Senchik
V. G. Bespalov
A. N. Stukov
E. A. Gubareva
M. A. Maydin
author_sort G. S. Kireeva
title Ascitic ovarian cancer is an adequate preclinical model of carcinomatosis to study intraperitoneal chemoperfusion treatment
title_short Ascitic ovarian cancer is an adequate preclinical model of carcinomatosis to study intraperitoneal chemoperfusion treatment
title_full Ascitic ovarian cancer is an adequate preclinical model of carcinomatosis to study intraperitoneal chemoperfusion treatment
title_fullStr Ascitic ovarian cancer is an adequate preclinical model of carcinomatosis to study intraperitoneal chemoperfusion treatment
title_full_unstemmed Ascitic ovarian cancer is an adequate preclinical model of carcinomatosis to study intraperitoneal chemoperfusion treatment
title_sort ascitic ovarian cancer is an adequate preclinical model of carcinomatosis to study intraperitoneal chemoperfusion treatment
publisher Tomsk National Research Medical Center of the Russian Academy of Sciences
series Sibirskij Onkologičeskij Žurnal
issn 1814-4861
2312-3168
publishDate 2019-02-01
description To study the mechanisms underlying the effects of intraperitoneal chemoperfusion and to develop the optimal chemoperfusion regimen, an animal model of peritoneal carcinomatosis closely resembles a human model of peritoneal carcinomatosis is required. In our study, the model of peritoneal carcinomatosis in rats with ascitic ovarian cancer was used. material and methods. There were three groups of rats with ascitic ovarian cancer: 1 – the control group (n=15) having no treatment; 2 – rats receiving normothermic intraperitoneal chemoperfusion with cisplatin, 40 mg/kg (n=12); 3 – rats receiving hyperthermic intraperitoneal chemoperfusion with cisplatin, 20 mg/kg (n=14). All animals were euthanized with subsequent autopsy. results. Ascitic ovarian cancer developed in 100 % of the animals injected with the tumor cells. The median overall survival of rats in the control group was 9.5 days. At autopsy, all rats had ascites, and rats surviving 15‒17 days after the tumor cell injection had white tumor nodes measuring 1–3 mm in the greater omentum, intestinal mesentery, parietal and visceral peritoneum. The nodes were histologically verified as metastases of low-differentiated ovarian tumor. In 2 and 5 rats from groups 2 and 3 respectively, metastases in paratracheal lymph nodes and tumor hydrothorax were detected with no evidence of peritoneal carcinomatosis. The median survival of rats in groups 2 and 3 was significantly higher than that in the control group, being 37.5 and 25.5 months, respectively (р=0,256). conclusion. This in vivo study proved that localization of ascitic ovarian tumor, development of the tumor in all animals injected with tumor cells, fast ascites progression and peritoneal carcinomatosis make this ascitic ovarian cancer an adequate preclinical model of peritoneal carcinomatosis to study intraperitoneal chemoperfusion. Further studies are needed to understand the reasons and mechanisms of the tumor hydrothorax development in rats after intraperitoneal chemoperfusion.
topic ascitic ovarian cancer
peritoneal carcinomatosis
intraperitoneal chemoperfusion
preclinical model
cisplatin
rats
survival
url https://www.siboncoj.ru/jour/article/view/963
work_keys_str_mv AT gskireeva asciticovariancancerisanadequatepreclinicalmodelofcarcinomatosistostudyintraperitonealchemoperfusiontreatment
AT oabelyaeva asciticovariancancerisanadequatepreclinicalmodelofcarcinomatosistostudyintraperitonealchemoperfusiontreatment
AT kyusenchik asciticovariancancerisanadequatepreclinicalmodelofcarcinomatosistostudyintraperitonealchemoperfusiontreatment
AT vgbespalov asciticovariancancerisanadequatepreclinicalmodelofcarcinomatosistostudyintraperitonealchemoperfusiontreatment
AT anstukov asciticovariancancerisanadequatepreclinicalmodelofcarcinomatosistostudyintraperitonealchemoperfusiontreatment
AT eagubareva asciticovariancancerisanadequatepreclinicalmodelofcarcinomatosistostudyintraperitonealchemoperfusiontreatment
AT mamaydin asciticovariancancerisanadequatepreclinicalmodelofcarcinomatosistostudyintraperitonealchemoperfusiontreatment
_version_ 1721263266090450944